On August 13, 2025, President Trump signed an executive order aimed at strengthening America’s pharmaceutical supply chains. Officially titled “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic...more
8/18/2025
/ Department of Health and Human Services (HHS) ,
Executive Orders ,
Government Agencies ,
Healthcare ,
Manufacturers ,
Most-Favored Nations ,
Patient Access ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Procurement Guidelines ,
Public Health ,
Supply Chain
The Trump administration has issued numerous pharma-focused executive orders, including “Lowering Drug Prices by Once Again Putting Americans First,” “Regulatory Relief to Promote Domestic Production of Critical Medicines,”...more
8/11/2025
/ Drug Pricing ,
Enforcement Actions ,
Executive Orders ,
Federal Pilot Programs ,
Food and Drug Administration (FDA) ,
Healthcare Reform ,
Most-Favored Nations ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Health ,
Regulatory Reform ,
Supply Chain ,
Tariffs ,
Trump Administration
In In re Entresto (Sacubitril/Valsartan) Patent Litigation, Judge Richard G. Andrews of the U.S. District Court for the District of Delaware granted MSN Pharmaceuticals Inc. a victory on noninfringement of U.S. Patent No....more
7/16/2025
/ Abbreviated New Drug Application (ANDA) ,
Adverse Inference Instructions ,
Claim Construction ,
Generic Drugs ,
Healthcare ,
Intellectual Property Protection ,
Life Sciences ,
Novartis ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
President Trump’s highly publicized executive order 14297, titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” targets the discrepancy in drug pricing in the United States compared with...more
5/16/2025
/ Antitrust Provisions ,
Department of Health and Human Services (HHS) ,
Direct to Consumer Sales ,
Drug Pricing ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
International Trade ,
Most-Favored Nations ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Requirements ,
Trump Administration ,
U.S. Commerce Department
President Trump’s May 5, 2025, executive order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines” sets out the administration’s goals to increase the domestic manufacture of critical...more
5/8/2025
/ Country of Origin ,
Drug Pricing ,
Environmental Policies ,
Environmental Protection Agency (EPA) ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Healthcare ,
Life Sciences ,
Manufacturers ,
Manufacturing Facilities ,
Patient Access ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Reform ,
Supply Chain ,
Trump Administration